The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising colorectal cancer prevalence, increased awareness and early screening efforts, and advances in precision medicine including non-invasive diagnostics and targeted therapies. North America currently leads the market, supported by advanced healthcare infrastructure and strong pharmaceutical presence, while Asia-Pacific is the fastest-growing region due to expanding healthcare investments and rising disease incidence. Ongoing innovations such as AI-assisted diagnostics and immunotherapy approvals are expected to further enhance market expansion and improve patient outcomes globally.
The global HPV testing and Pap test market is projected to grow at a compound annual growth rate (CAGR) of about 7% from 2026 to 2034, reaching an estimated value of $6.5 billion by 2034. This growth is driven by the increasing prevalence of cervical...
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
Jim Cramer highlights that today's stock market is punishing companies that miss expectations more aggressively than during the 1999 dot-com bubble. While the S&P 500 and Nasdaq hit record highs, the market is narrowly focused on artificial intellige...
Abbott Laboratories is currently valued at a decade low of 17.7 times forward earnings despite strong 13.2% growth in its Medical Devices segment in Q1 2026 and a 54-year dividend streak. Key growth drivers include synergies with Exact Sciences, expa...
